Updated time: 2021-02-26 16:07:49
28A-1050418
TW I661096、US 10752673 B2
Antibody-mediated drug delivery systems have been making substantial progress in treating cancers. Nevertheless, methods for engineering optimal antibodies for drug delivery has been lacking. The challenges are: (1) attaining a wide variety of antibody candidates targeting diverse epitopes on a target antigen has been difficult; and (2) evaluation of the payload deliver efficiency is rate-limited by conjugation step. The present invention relates to adaptor systems specifically coupled with the synthetic antibody repertoires to select optimal antibodies with cell-based assay in high throughput format. The whole system is an effective technological platform capable of engineering optimal antibodies for medicinal payload delivery.
Methods for engineering optimal antibodies in guiding drug delivery has been lacking. To select the most effective antibody candidates to deliver a biological toxin to cancer cells, we have established adaptor systems specifically coupled with the synthetic antibody repertoires.
Antibody-mediated drug delivery systems are important therapeutics in treating cancers. These systems include antibody-drug conjugates (ADCs), immunotoxins (ITs), and immunoliposomes (ILs).
An-Suei Yang, Hong-Sen Chen, Shin-Chen Hou, Chung-Ming Yu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A high-throughput antibody engineering platform for discovering and optimizing antibodies in antibody-guided drug delivery systems